Meghana Raghavendra, MD
Hematology & Oncology · Indianapolis, INNPI 1902916109
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in IN, where the typical reported total is $3,829.
Across 80 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$291
- Merck$235
- AstraZeneca$138
- Novartis$112
- Bristol Myers Squibb$84
- Pfizer$76
- plus $733 from 27 others
Across 12 payments — averaging $9443.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$52K
- Mirati Therapeutics, Inc.$34K
- GSK$15K
- Eli Lilly$8K
- Amgen$4K
What the payments were for
- Food & beverage$1,55193%
- Education$1197%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 9 | $291 |
| Merck | 15 | $235 |
| AstraZeneca | 5 | $138 |
| Novartis | 2 | $112 |
| Bristol Myers Squibb | 4 | $84 |
| Pfizer | 4 | $76 |
| Johnson & Johnson | 2 | $62 |
| Genentech USA, Inc. | 4 | $61 |
| Servier Pharmaceuticals LLC | 3 | $50 |
| GSK | 3 | $50 |
| Menarini Silicon Biosystems, Inc. | 1 | $41 |
| Foundation Medicine, Inc. | 1 | $39 |
| Agios Pharmaceuticals, Inc. | 2 | $38 |
| AbbVie | 2 | $36 |
| Array Biopharma Inc | 2 | $36 |
| Stemline Therapeutics Inc. | 2 | $33 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $29 |
| Sanofi | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Gilead | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Seagen Inc. | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Aurobindo Pharma USA, Inc. | 1 | $15 |
| Incyte Corporation | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Immunocore Limited | 1 | $14 |
| Bayer | 1 | $13 |
| Iovance Biotherapeutics, Inc. | 1 | $13 |
| Sirtex Medical Inc | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $10 |
How this compares
$1,670 in reported general payments places this provider in the 30th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 28 | $474,922 |
| LumakrasSotorasib | 19 | $394,655 |
| XtandiEnzalutamide | 26 | $389,606 |
| ImbruvicaIbrutinib | 24 | $340,646 |
| JakafiRuxolitinib Phosphate | 18 | $339,775 |
| Lenalidomide | 15 | $228,729 |
| VerzenioAbemaciclib | 14 | $212,305 |
| EliquisApixaban | 117 | $99,328 |
| BrukinsaZanubrutinib | 11 | $82,355 |
| Abiraterone Acetate | 13 | $78,531 |
| VenclextaVenetoclax | 12 | $63,164 |
| Imatinib Mesylate | 13 | $29,667 |
| Everolimus | 12 | $19,377 |
| XareltoRivaroxaban | 15 | $15,540 |
| Anastrozole | 162 | $2,021 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $84 | $474,92228 claims |
| Astellas Pharma US IncXtandi | $14 | $389,60626 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $29 | $340,64624 claims |
| Incyte CorporationJakafi | $15 | $339,77518 claims |
| PfizerEliquis | $76 | $99,328117 claims |
| AbbVieVenclexta | $36 | $63,16412 claims |
| Johnson & JohnsonXarelto | $62 | $15,54015 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $15 | $83247 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Indianapolis
- Richard GaynorIndianapolis$3.7M
- Ruemu BirhirayIndianapolis$3.1M
- Anand TandraIndianapolis$280K
- Attaya SuvannasankhaIndianapolis$253K
- Michael DuganIndianapolis$236K
- Daniel MiltonIndianapolis$231K
- Amro ElshouryIndianapolis$212K
- Brian MulherinIndianapolis$175K
- Muhammad Sarfraz NawazIndianapolis$172K
- John EdwardsIndianapolis$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.